Suchergebnisse

FAIRplus seeks to establish 'FAIRification' processes that can be used at scale to ensure FAIRness of IMI data. In order to establish, refine and validate FAIRplus FAIRification techniques, four pilot IMI datasets were selected in D1.1. This deliverable describes the outcomes achieved to date when FAIRifying these datasets using the newly established FAIRplus FAIRification process. The FAIRified pilot datasets are now listed in the IMI data catalogue, along with an evaluation of their level of FAIR after FAIRification processes were applied. In this deliverable, we show that FAIRplus FAIRification processes generally increase the level of FAIR for pilot datasets, although no datasets became "completely FAIR" as a result. Level of FAIR is quantified by a series of FAIR indicators, established from a FAIR assessment conducted on each dataset before and after FAIRification. The results of these assessments are linked from the IMI data catalogue. All processes used during FAIRification are documented as recipes in the FAIR Cookbook. ; This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 802750. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation and EFPIA companies.

FAIRplus seeks to establish 'FAIRification' processes that can be used at scale to ensure FAIRness of IMI data. In order to establish, refine and validate FAIRplus FAIRification techniques, four pilot IMI datasets were selected in D1.1. This deliverable describes the outcomes achieved to date when FAIRifying these datasets using the newly established FAIRplus FAIRification process. The FAIRified pilot datasets are now listed in the IMI data catalogue, along with an evaluation of their level of FAIR after FAIRification processes were applied. In this deliverable, we show that FAIRplus FAIRification processes generally increase the level of FAIR for pilot datasets, although no datasets became "completely FAIR" as a result. Level of FAIR is quantified by a series of FAIR indicators, established from a FAIR assessment conducted on each dataset before and after FAIRification. The results of these assessments are linked from the IMI data catalogue. All processes used during FAIRification are documented as recipes in the FAIR Cookbook. ; This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 802750. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation and EFPIA companies.

eTRANSAFE is a research project funded within the Innovative Medicines Initiative (IMI), which aims at developing integrated databases and computational tools (the eTRANSAFE ToxHub) that support the translational safety assessment of new drugs by using legacy data provided by the pharmaceutical companies that participate in the project. The project objectives include the development of databases containing preclinical and clinical data, computational systems for translational analysis including tools for data query, analysis and visualization, as well as computational models to explain and predict drug safety events. ; This research received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements eTRANSAFE (777365). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA companies in kind contribution.

eTRANSAFE is a research project funded within the Innovative Medicines Initiative (IMI), which aims at developing integrated databases and computational tools (the eTRANSAFE ToxHub) that support the translational safety assessment of new drugs by using legacy data provided by the pharmaceutical companies that participate in the project. The project objectives include the development of databases containing preclinical and clinical data, computational systems for translational analysis including tools for data query, analysis and visualization, as well as computational models to explain and predict drug safety events. ; This research received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements eTRANSAFE (777365). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA companies in kind contribution. The Research Programme on Biomedical Informatics (GRIB) of IMIM and DCEXS-UPF is a member of the Spanish National Bioinformatics Institute (INB), PRB2-ISCIII and is supported by grant PT13/0001/0023, of the PE I + D + i 2013–2016, funded by ISCIII and FEDER. The GRIB also receive support from Agència de Gestió D'ajuts Universitaris i de Recerca Generalitat de Catalunya (AGAUR, ref.: 2017SGR01020). The DCEXS is a "Unidad de Excelencia María de Maeztu", funded by the MINECO (ref: MDM-2014-0370). ; Peer Reviewed ; Postprint (published version)